{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:35:47Z","timestamp":1793730947994,"version":"4.6.1"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5507","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T05:35:18Z","timestamp":1452836118000},"page":"121-126","source":"Crossref","is-referenced-by-count":43,"title":["Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis"],"prefix":"10.2169","volume":"55","author":[{"given":"Hiroe","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"James Kazama","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Murasawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Nakazono","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Niigata University Health Administration Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 21: 1287-1293, 2010.","DOI":"10.1007\/s00198-010-1192-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 69: 1415-1419, 2010.","DOI":"10.1136\/ard.2010.135061"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49, 2006.","DOI":"10.1152\/ajpendo.00008.2006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004.","DOI":"10.1359\/JBMR.0301264"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-F1095, 2005.","DOI":"10.1152\/ajprenal.00474.2004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006.","DOI":"10.1038\/sj.ki.5002000"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kolek OI, Hines ER, Jones MD, et al. 1&alpha;,25-Dihydroxyvitamin D<sub>3<\/sub> upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005.","DOI":"10.1152\/ajpgi.00243.2005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1&alpha;,25-dihydroxyvitamin D<sub>3<\/sub> and phosphorus <i>in vivo<\/i>. J Biol Chem 280: 2543-2549, 2005.","DOI":"10.1074\/jbc.M408903200"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sitara D, Kim S, Razzaque MS, et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 4: e1000154, 2008.","DOI":"10.1371\/journal.pgen.1000154"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in <i>Phex<\/i>-deficient mice. Matrix Biol 23: 421-432, 2004.","DOI":"10.1016\/j.matbio.2004.09.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505, 2001.","DOI":"10.1073\/pnas.101545198"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.","DOI":"10.1002\/art.1780310302"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140: 659-662, 1949.","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002.","DOI":"10.1210\/jc.2002-021105"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011.","DOI":"10.1038\/ki.2011.47"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Isakova T, Xie H, Barchi-Chung A, et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6: 2688-2695, 2011.","DOI":"10.2215\/CJN.04290511"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Park SY, Jeong KH, Moon JY, et al. The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol 14: 239-243, 2010.","DOI":"10.1007\/s10157-010-0272-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prie D. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73: 102-107, 2008.","DOI":"10.1038\/sj.ki.5002622"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sato H, Kuroda T, Tanabe N, et al. Cystatin C is a sensitive marker for detecting a reduced glomerular filtration rate when assessing chronic kidney disease in patients with rheumatoid arthritis and secondary amyloidosis. Scand J Rheumatol 39: 33-37, 2010.","DOI":"10.3109\/03009740903042402"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Munoz Mendoza J, Isakova T, Ricardo AC, et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7: 1155-1162, 2012.","DOI":"10.2215\/CJN.13281211"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 21: 1853-1861, 2010.","DOI":"10.1007\/s00198-009-1142-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28: 1793-1803, 2013.","DOI":"10.1002\/jbmr.1923"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Braithwaite V, Prentice AM, Doherty C, Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012: 27, 2012.","DOI":"10.1186\/1687-9856-2012-27"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kanda E, Yoshida M, Sasaki S. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients. BMC Nephrol 13: 122, 2012.","DOI":"10.1186\/1471-2369-13-122"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Delgado-Calle J, Arozamena J, Garcia-Renedo R, et al. Osteocyte deficiency in hip fractures. Calcif Tissue Int 89: 327-334, 2011.","DOI":"10.1007\/s00223-011-9522-0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kitaoka T, Namba N, Miura K, et al. Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta. J Bone Miner Metab 29: 598-605, 2011.","DOI":"10.1007\/s00774-011-0262-z"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Rice DP, Aberg T, Chan Y, et al. Integration of FGF and TWIST in calvarial bone and suture development. Development 127: 1845-1855, 2000.","DOI":"10.1242\/dev.127.9.1845"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23: 939-948, 2008.","DOI":"10.1359\/jbmr.080220"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285: E1-E9, 2003.","DOI":"10.1152\/ajpendo.00016.2003"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87: 99-107, 2010.","DOI":"10.1007\/s00223-010-9372-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women: the six-month effect of risedronate and teriparatide. Osteoporos Int 23: 1171-1176, 2012.","DOI":"10.1007\/s00198-010-1525-6"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805-814, 2004.","DOI":"10.1084\/jem.20031454"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/2\/55_55.5507\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T18:43:10Z","timestamp":1654108990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/2\/55_55.5507\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5507","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}